Display options
Cite
Newton AD, Bartlett EK, Karakousis GC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol. 2016;7(1):99-111doi: 10.3978/j.issn.2078-6891.2015.100.
Newton, A. D., Bartlett, E. K., & Karakousis, G. C. (2016). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. Journal of gastrointestinal oncology, 7(1), 99-111. https://doi.org/10.3978/j.issn.2078-6891.2015.100
Newton, Andrew D, et al. "Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality." Journal of gastrointestinal oncology vol. 7,1 (2016): 99-111. doi: https://doi.org/10.3978/j.issn.2078-6891.2015.100
Newton AD, Bartlett EK, Karakousis GC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol. 2016 Feb;7(1):99-111. doi: 10.3978/j.issn.2078-6891.2015.100. PMID: 26941988; PMCID: PMC4754303.
Copy Download .nbib Format: NLM
Share it on

J Gastrointest Oncol. 2016 Feb;7(1):99-111. doi: 10.3978/j.issn.2078-6891.2015.100.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality.

Journal of gastrointestinal oncology

Andrew D Newton, Edmund K Bartlett, Giorgos C Karakousis

Affiliations

  1. Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.

PMID: 26941988 PMCID: PMC4754303 DOI: 10.3978/j.issn.2078-6891.2015.100

Abstract

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with prolonged survival for appropriately selected patients with peritoneal dissemination of abdominal malignancies. CRS and HIPEC has been criticized for perceived high rates of morbidity and mortality. Morbidity and mortality rates of CRS and HIPEC, however, do not appear dissimilar to those of other large abdominal surgeries, particularly when relevant patient and operative factors are accounted for. The risk of morbidity and mortality following this surgery for a given individual can be predicted in part by a variety of patient and operative factors. While strong data are lacking, the limited data that exists on the matter suggests that the independent contribution of the heated intraperitoneal chemotherapy to CRS and HIPEC morbidity is relatively small. A more thorough understanding of the patient and operative factors associated with CRS and HIPEC morbidity and mortality, as well as the specific complications related to the intraperitoneal chemotherapy, can better inform clinicians in multidisciplinary teams and patients alike in the decision-making for this surgery.

Keywords: Hyperthermic intraperitoneal chemotherapy (HIPEC); morbidity; mortality

References

  1. Ann Surg. 2012 Aug;256(2):334-41 - PubMed
  2. Ann Surg Oncol. 2013 Apr;20(4):1093-100 - PubMed
  3. Ann Surg Oncol. 2006 May;13(5):635-44 - PubMed
  4. Ann Surg Oncol. 2013 Nov;20(12):3899-904 - PubMed
  5. J Am Coll Surg. 2014 Apr;218(4):573-85 - PubMed
  6. J Surg Oncol. 2014 Dec;110(7):779-85 - PubMed
  7. Surg Oncol Clin N Am. 2012 Oct;21(4):559-76 - PubMed
  8. Ann Surg Oncol. 2015 Mar;22(3):987-93 - PubMed
  9. Ann Surg Oncol. 2013 Oct;20(11):3519-26 - PubMed
  10. J Surg Oncol. 2012 Aug 1;106(2):197-203 - PubMed
  11. Br J Surg. 2007 Nov;94(11):1408-14 - PubMed
  12. Ann Surg Oncol. 2014 Apr;21(4):1147-52 - PubMed
  13. Ann Surg Oncol. 2015 Aug;22(8):2656-62 - PubMed
  14. Ann Surg Oncol. 2015 May;22(5):1651-7 - PubMed
  15. Ann Surg Oncol. 2014 Apr;21(4):1153-8 - PubMed
  16. Ann Surg Oncol. 2015 May;22(5):1716-21 - PubMed
  17. Ann Surg Oncol. 2007 Sep;14(9):2550-8 - PubMed
  18. Ann Surg Oncol. 2013 Apr;20(4):1068-73 - PubMed
  19. Ann Surg Oncol. 2014 Jun;21(6):1792-800 - PubMed
  20. J Clin Oncol. 2009 Feb 10;27(5):681-5 - PubMed
  21. Ann Surg Oncol. 2008 Feb;15(2):535-41 - PubMed
  22. Ann Surg Oncol. 2014 Dec;21(13):4226-31 - PubMed
  23. Ann Surg Oncol. 2012 Jan;19(1):122-5 - PubMed
  24. Eur J Surg Oncol. 2013 Dec;39(12):1435-43 - PubMed
  25. Oncology. 2002;63(4):346-52 - PubMed
  26. Ann Surg Oncol. 2009 Jul;16(7):1903-11 - PubMed
  27. Tumori. 1999 Jan-Feb;85(1):41-6 - PubMed
  28. J Surg Oncol. 2014 May;109(6):527-32 - PubMed
  29. J Surg Oncol. 2013 Aug;108(2):81-8 - PubMed
  30. Ann Surg Oncol. 2011 Jun;18(6):1575-81 - PubMed
  31. Ann Surg. 2012 Feb;255(2):348-56 - PubMed
  32. Surgery. 2012 Oct;152(4):617-24; discussion 624-5 - PubMed
  33. Ann Surg Oncol. 2010 Oct;17(10):2720-7 - PubMed
  34. J Surg Res. 2013 Jan;179(1):e133-9 - PubMed
  35. Ann Surg Oncol. 2013 Dec;20(13):4224-30 - PubMed
  36. Ann Surg Oncol. 2015 May;22(5):1673-9 - PubMed
  37. Ann Surg Oncol. 2015 May;22(5):1645-50 - PubMed
  38. Ann Surg Oncol. 2008 Sep;15(9):2426-32 - PubMed
  39. Ann Surg Oncol. 2015 May;22(5):1634-8 - PubMed
  40. Ann Surg Oncol. 2010 Sep;17(9):2370-7 - PubMed
  41. J Surg Oncol. 2015 Feb;111(2):237-42 - PubMed
  42. J Surg Oncol. 2004 Feb;85(2):61-7 - PubMed
  43. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S898-904 - PubMed
  44. Eur J Surg Oncol. 2014 Aug;40(8):970-5 - PubMed
  45. Ann Surg Oncol. 2013 Apr;20(4):1088-92 - PubMed
  46. Ann Surg Oncol. 2014 Dec;21(13):4218-25 - PubMed
  47. Ann Surg. 2010 May;251(5):896-901 - PubMed
  48. Eur J Surg Oncol. 2010 Jun;36(6):589-93 - PubMed
  49. Am Surg. 2014 Apr;80(4):348-52 - PubMed
  50. J Clin Oncol. 2003 Oct 15;21(20):3737-43 - PubMed
  51. Ann Surg Oncol. 2014 Sep;21(9):3023-8 - PubMed
  52. Ann Surg Oncol. 1999 Sep;6(6):582-90 - PubMed
  53. Ann Surg Oncol. 2015 Apr;22(4):1274-9 - PubMed
  54. Eur J Surg Oncol. 2010 May;36(5):456-62 - PubMed
  55. Anticancer Res. 2015 Jan;35(1):295-300 - PubMed
  56. Ann Surg Oncol. 2014 May;21(5):1494-500 - PubMed
  57. Ann Surg Oncol. 2009 Oct;16(10):2765-70 - PubMed
  58. J Clin Oncol. 2009 Dec 20;27(36):6237-42 - PubMed
  59. Ann Surg Oncol. 2012 Jan;19(1):104-9 - PubMed
  60. Gastroenterol Res Pract. 2012;2012:827534 - PubMed
  61. J Clin Oncol. 2010 Jan 1;28(1):63-8 - PubMed
  62. Arch Surg. 2012 Oct;147(10):919-23 - PubMed
  63. J Clin Oncol. 2012 Jul 10;30(20):2449-56 - PubMed
  64. BMC Cancer. 2014 Nov 04;14 :807 - PubMed
  65. Ann Surg Oncol. 2009 Aug;16(8):2181-7 - PubMed
  66. Ann Surg Oncol. 2011 Apr;18(4):1052-9 - PubMed
  67. Ann Surg Oncol. 2007 Aug;14(8):2270-80 - PubMed
  68. Ann Surg Oncol. 2008 Nov;15(11):3065-72 - PubMed
  69. Cancer. 2010 Dec 15;116(24):5608-18 - PubMed
  70. Ann Surg Oncol. 2015 May;22(5):1664-72 - PubMed
  71. Ann Surg Oncol. 2008 Mar;15(3):745-53 - PubMed
  72. Ann Surg Oncol. 2006 Jan;13(1):58-65 - PubMed
  73. J Surg Oncol. 2013 May;107(6):574-8 - PubMed
  74. Ann Surg Oncol. 2014 Mar;21(3):868-74 - PubMed
  75. Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:88-93 - PubMed
  76. Ann Surg Oncol. 2013 Oct;20(11):3497-503 - PubMed
  77. Ann Surg Oncol. 2014 May;21(5):1456-62 - PubMed
  78. Ann Surg. 2016 Feb;263(2):369-75 - PubMed
  79. Ann Surg Oncol. 2015 May;22(5):1639-44 - PubMed
  80. Ann Surg Oncol. 2014 Mar;21(3):908-14 - PubMed
  81. Ann Surg Oncol. 2014 May;21(5):1463-7 - PubMed
  82. J Surg Oncol. 2014 Jun;109(7):730-9 - PubMed
  83. Ann Surg Oncol. 2015 May;22(5):1680-5 - PubMed
  84. Ann Surg. 2011 Aug;254(2):294-301 - PubMed
  85. J Am Coll Surg. 2012 Sep;215(3):412-7 - PubMed
  86. Anticancer Res. 2014 Oct;34(10):5689-93 - PubMed

Publication Types